AlphaMadera
Pfizer Inc. (PFE)
$29.88
-0.91 (-2.96%)Delayed quote.
Price history
Daily close- Start
- $24.85
- Latest close
- $29.88
- Period change
- +20.24%
- Period low
- $23.67
- Period high
- $30.79
Key metrics
- Market cap
- $170.31B
- Volume
- 52.81M
- Average volume
- 36.20M
- 52-week range
- $23.62 – $31.44
- Beta
- 0.28
- Last dividend
- $1.72
- EPS (TTM)
- $0.71
- P/E ratio
- 42.28
- Revenue (TTM)
- $63.62B
- Net income (TTM)
- $4.03B
- Total assets
- $204.54B
- Total debt
- $62.67B
- Cash and equivalents
- $1.82B
Key financials (trailing twelve months).
Company profile
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- CEO
- Albert Bourla
- Employees
- 75,000
- Headquarters
- New York City, NY, US
- IPO date
- 1972-06-01
- Website
- https://www.pfizer.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $62.58B | $63.63B | $59.55B |
| Gross profit | $46.51B | $45.78B | $34.60B |
| Operating income | $17.41B | $14.94B | $4.42B |
| EBITDA | $16.78B | $18.13B | $9.56B |
| Net income | $7.77B | $8.03B | $2.12B |
| Diluted EPS | $1.36 | $1.41 | $0.37 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $1.14B | $1.04B | $2.85B |
| Total assets | $208.16B | $213.40B | $226.50B |
| Total liabilities | $121.39B | $124.90B | $137.21B |
| Total debt | $67.42B | $66.99B | $70.84B |
| Shareholders’ equity | $86.48B | $88.20B | $89.01B |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $11.71B | $12.74B | $8.70B |
| Capital expenditure | -$2.63B | -$2.91B | -$3.91B |
| Free cash flow | $9.08B | $9.84B | $4.79B |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 27, 2026 | Q2 2026Jun 28, 2026 | Q1 2026Mar 29, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 28, 2025 | Q2 2025Jun 29, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $16.58B | $15.03B | $14.45B | $17.56B | $16.65B | $14.65B |
| Gross profit | $12.55B | $10.94B | $10.90B | $12.29B | $12.48B | $10.88B |
| Operating income | $3.67B | $3.54B | $4.27B | $3.69B | $5.53B | $3.77B |
| EBITDA | $5.62B | $1.64B | $5.45B | $756.00M | $5.65B | $5.32B |
| Net income | $3.24B | -$248.00M | $2.69B | -$1.65B | $3.54B | $2.91B |
| Diluted EPS | $0.56 | -$0.04 | $0.47 | -$0.29 | $0.62 | $0.51 |
| Metric | Q3 2026Sep 27, 2026 | Q2 2026Jun 28, 2026 | Q1 2026Mar 29, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 28, 2025 | Q2 2025Jun 29, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $1.82B | $976.00M | $1.70B | $1.14B | $1.34B | $1.64B |
| Total assets | $204.54B | $201.13B | $207.62B | $208.16B | $208.73B | $206.09B |
| Total liabilities | $115.24B | $115.64B | $117.21B | $121.39B | $115.64B | $117.08B |
| Total debt | $62.67B | $63.19B | $64.45B | $67.42B | $61.71B | $61.80B |
| Shareholders’ equity | $89.00B | $85.19B | $90.10B | $86.48B | $92.80B | $88.69B |
| Metric | Q3 2026Sep 27, 2026 | Q2 2026Jun 28, 2026 | Q1 2026Mar 29, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 28, 2025 | Q2 2025Jun 29, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $5.38B | $835.00M | $2.62B | $5.35B | $4.60B | -$582.00M |
| Capital expenditure | -$573.00M | -$533.00M | -$436.00M | -$845.00M | -$602.00M | -$618.00M |
| Free cash flow | $4.80B | $302.00M | $2.18B | $4.50B | $4.00B | -$1.20B |